MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles

Rasaneh, Samira; Rajabi, Hamid; Babaei, Mohammad; Akhlaghpoor, Shahram

doi:10.1007/s11051-010-9991-5

Cited by 16 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their findings showed significant uptake of the nanoparticles in the cancer cells compared to the untargeted nanoparticles. Biodistributions from mouse studies showed a higher density of nanoparticles in the tumor than any of the organs, including the liver 15 .…”

Section: Nanoparticles Targeting Protein Overexpression Deregulationmentioning

confidence: 91%

Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer

Shin

Beech

Kelly

2012

Integrative Biology

View full text Add to dashboard Cite

The way we view cancer has advanced greatly in the past few decades from simplistic approaches to finely honed systems. This transition has been made possible because of advancements on two fronts: the first is the rapidly expanding knowledge base of the mechanisms and characteristics of cancer; the second is innovation in imaging agent design. Rapid advancements in imaging and therapeutic agents are being made through the evolution from one-dimensional molecules to multi-functional nanoparticles. Powerful new agents that have high specificity and minimal toxicity are being developed for in vivo imaging. Here we detail the unique characteristics of cancer that allow differentiation from normal tissue and how they are exploited in nanoparticle imaging development. Firstly, genetic alterations, either endogenous or induced through gene therapy, are one such class of characteristics. Proteomic differences such as overexpressed surface receptors is another targetable feature used for enhanced nanoparticle retention. Increased need for nutrients and specific growth signals to sustain proliferation and angiogenesis are further examples of how cancer can be targeted. Lastly, migration and invasion through a unique microenvironment are two additional traits that are exploitable, due to differences in metalloproteinase concentrations and other factors. These differences are guiding current nanoparticle design to better target, image and treat cancer.

show abstract

Section: Nanoparticles Targeting Protein Overexpression Deregulationmentioning

confidence: 91%

Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer

Shin

Beech

Kelly

2012

Integrative Biology

View full text Add to dashboard Cite

show abstract

“…In the first stage, diaminohexane-dextran was synthesized as described previously [19] and then diaminohexane-dextran-coated iron oxide nanoparticles were prepared using the coprecipitation method [10] with some modification. In brief, FeCl 2 (0.5 M) and FeCl 3 (1 M) solution in water were mixed with two volumes of diaminohexane-dextran.…”

Section: Synthesis Of Mnpsmentioning

confidence: 99%

The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody

Rasaneh

Dadras

2015

Biomedical Engineering / Biomedizinische Technik

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conjugation of targeting moieties to the iron oxide core is possible because of the polymeric coatings used to stabilize the SPIO nanoparticles. Rajabi and Tsourkas and co-workers reported the use of targeted SPIO nanoparticles for selective detection of tumors in vivo [63, 64]. The contrast agents reported by these groups target the HER2 receptor in tumor tissues and consisted of magnetic nanoparticles modified with the monoclonal antibody Trastuzumab, 29 , or with a HER2-affibody, 30 (Fig.…”

Section: The Conjugation Strategymentioning

confidence: 99%

“…4). To synthesize particle 29 , the targeting antibody was conjugated to the nanoparticle using an amine-containing linker incorporated into a dextran coating [63]. Whereas, in particle 30 , the azide–alkyne Huisgen cycloaddition (often referred to as “click” chemistry) was used to conjugate an alkynated linker containing the HER2-targeted affibody to a polymer coating functionalized with azides [64].…”

Section: The Conjugation Strategymentioning

confidence: 99%

Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging

Vithanarachchi¹,

Allen²

2012

CMI

View full text Add to dashboard Cite

This review describes recent research efforts focused on increasing the specificity of contrast agents for proton magnetic resonance imaging (MRI). Contrast agents play an indispensable role in MRI by enhancing the inherent contrast of images; however, the non-specific nature of current clinical contrast agents limits their usefulness. This limitation can be addressed by conjugating contrast agents or contrast-agent-loaded carriers—including polymers, nanoparticles, dendrimers, and liposomes—to molecules that bind to biological sites of interest. An alternative approach to conjugation is synthetically mimicking biological structures with metal complexes that are also contrast agents. In this review, we describe the advantages and limitations of these two targeting strategies with respect to translation from in vitro to in vivo imaging while focusing on advances from the last ten years.

show abstract

MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles

Cited by 16 publications

References 25 publications

Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer

Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer

The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody

Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging

Contact Info

Product

Resources

About